Evidence base: Crohn's disease

A summary of the clinical trials, guidelines, key texts and online resources to help in the management of Crohn's disease

In early mild CD the mucosa may show multiple aphthoid ulcers only
In early mild CD the mucosa may show multiple aphthoid ulcers only

Clinical trials

  • ACCENT I (A CD clinical trial evaluating infliximab in a new long-term teatment regimen).6

The ACCENT I study compared episodic versus scheduled infliximab therapy.

This trial clearly demonstrated that scheduled treatment was more effective than episodic treatment in inducing and maintaining remission and mucosal healing.

It also provided useful evidence that clinical response can be achieved by increasing the infliximab dosage in patients who are no longer responding to standard infliximab therapy.

This study showed that infliximab was highly effective in fistulising CD, with a response rate of 68 per cent compared with 26 per cent in the placebo group.

This study randomised immunomodulator naive patients to receive AZA, infliximab or both.

The trial demonstrated that infliximab (monotherapy or combination with AZA) was more effective than AZA alone. It also demonstrated the benefit of initiating infliximab early in the treatment of CD.

The incidence of serious infections was not increased in patients receiving infliximab and AZA combination therapy.

Guidelines

  • British Society of Gastroenterology guidelines.

Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; doi: 10.1136/gut. 2010.224154.

  • Dignass A, Van Assche G, Lindsay JO, et al.

The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010: 4: 28-62.

The previous 2002 guidance was too restrictive, allowing the use of infliximab in patients with severe active CD but not in patients with fistulising disease alone.

The new 2010 NICE guidance suggests a scheduled course of treatment of one year is the most cost-effective therapy, after which a full reassessment of disease is required.

The guidance also allows for the use of infliximab for fistulising disease and in paediatric patients. The new guidance refers to the licensed indications which involve failure of steroids and/or immune suppressants, raising the option of using biologics earlier in the disease course.

Key text

  • Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's Gastrointestinal and Liver Disease (9th edition). Philadelphia, Saunders, 2010. A comprehensive overview of CD.
Contributed by Dr Guy Chung-Faye, consultant gastroenterologist, and Jaroslava Tumova, IBD nurse specialist, King's College Hospital, London.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus